Nobivac Parvo-C is most often used in puppies to provide additional immunisation in animals at high risk of early exposure to canine parvovirus from as early as 4 weeks of age.
Freeze-dried pellet for suspension for injection
Nobivac Parvo-C contains live, attenuated, freeze dried, virus vaccine containing canine parvovirus, grown in cell line tissue culture.
Per dose of 1 ml:
Canine parvovirus not less than 107.0 TCID50*
*Tissue Culture Infective Dose 50 %
Indications for use
Nobivac Parvo-C is indicated for active immunisation of dogs to prevent mortality, clinical signs and viral excretion following canine parvovirus infection.
Specific claims: An onset of immunity to the canine parvovirus vaccine component of 1 week has been demonstrated following use of the vaccine. A duration of immunity of at least three years has been established for the canine parvovirus vaccine component.
APET-plastic tray containing 10 vials
For full information please refer to the product data sheet. Further information is available on request.
Use Medicines Responsibly. For more information please refer to the Responsible Use sections of the NOAH website.
If you are not the prescribing veterinary surgeon, advice should be sought from the medicine prescriber.
Date of preparation: January 2018